We have been able to demonstrate that transgenic mice overexpressing the human ApoD will develop a non-inflammatory hepatic steatosis caused by an increase in fatty acid uptake due to increased hepatic CD36 expression, altered ARA metabolism, and amelioration of the ω-6/ω-3 ratio [74]. Here, APOD is linked to fatty liver disease.